FDA Finalizes Guidance on Evaluation of Bulk Drug Substance Candidates

Drug Industry Daily
The FDA has issued final guidance clarifying its thought process for evaluating bulk drug substances that are being considered for the 503B bulks list, which specifies substances that outsourcing facilities may use in drug compounding.

To View This Article:


Subscribe To Drug Industry Daily